0000919574-24-005529.txt : 20240917 0000919574-24-005529.hdr.sgml : 20240917 20240917194806 ACCESSION NUMBER: 0000919574-24-005529 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240912 FILED AS OF DATE: 20240917 DATE AS OF CHANGE: 20240917 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lu Hongbo CENTRAL INDEX KEY: 0001767584 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39926 FILM NUMBER: 241305865 MAIL ADDRESS: STREET 1: C/O AVEDRO, INC., 201 JONES ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Terns Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001831363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-525-5535 EXT.101 MAIL ADDRESS: STREET 1: 1065 EAST HILLSDALE BLVD., SUITE 100 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 ownership.xml X0508 4 2024-09-12 0 0001831363 Terns Pharmaceuticals, Inc. TERN 0001767584 Lu Hongbo C/O TERNS PHARMACEUTICALS, INC. 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 1 0 0 0 0 Common Stock 2024-09-12 4 P 0 190476 10.50 A 190476 I See footnote Common Stock 2024-09-12 4 P 0 285714 10.50 A 476190 I See footnote The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The reported securities are owned directly by NEXTBio Opportunity Adapt LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital Opportunity Adapt GP, LLC, the managing member of NEXTBio Opportunity Adapt LLC, and (ii) Hongbo Lu, a managing member of NEXTBio Capital Opportunity Adapt GP, LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Hongbo Lu By: /s/ Hongbo Lu 2024-09-17